Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher on Analyst Upgrade

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report)'s stock price traded up 7.3% during trading on Thursday after Cantor Fitzgerald raised their price target on the stock from $25.00 to $30.00. Cantor Fitzgerald currently has an overweight rating on the stock. Capricor Therapeutics traded as high as $18.25 and last traded at $18.15. 216,121 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 1,141,077 shares. The stock had previously closed at $16.91.

Other equities analysts also recently issued research reports about the stock. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an "overweight" rating and a $35.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Maxim Group upped their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Finally, Oppenheimer restated an "outperform" rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $34.50.

Insider Transactions at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm's stock in a transaction dated Friday, September 20th. The stock was bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 65.21 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 12.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently modified their holdings of CAPR. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics in the first quarter worth $40,000. Vanguard Group Inc. grew its holdings in Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock worth $9,274,000 after purchasing an additional 200,499 shares during the period. Bank of New York Mellon Corp grew its holdings in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after purchasing an additional 9,040 shares during the period. Rhumbline Advisers bought a new position in shares of Capricor Therapeutics in the second quarter valued at $147,000. Finally, Main Street Financial Solutions LLC lifted its stake in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock valued at $131,000 after buying an additional 7,500 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Stock Up 9.3 %

The stock has a market capitalization of $839.63 million, a P/E ratio of -19.88 and a beta of 4.00. The business's 50 day simple moving average is $14.63 and its two-hundred day simple moving average is $8.29.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.